miR-483-5p Promotes Invasion and Metastasis of Lung Adenocarcinoma by Targeting RhoGDI1 and ALCAM

Qiancheng Song1, Yuanfei Xu1, Cuilan Yang1, Zhenguo Chen1, Chunhong Jia1, Juan Chen1, Yue Zhang1, Pinglin Lai1, Xiaorong Fan1, Xuan Zhou1, Jun Lin1, Ming Li1, Wenli Ma2, Shenqiu Luo1, and Xiaochun Bai1

Abstract

The nodal regulatory properties of microRNAs (miRNA) in metastatic cancer may offer new targets for therapeutic control. Here, we report that upregulation of miR-483-5p is correlated with the progression of human lung adenocarcinoma. miR-483-5p promotes the epithelial–mesenchymal transition (EMT) accompanied by invasive and metastatic properties of lung adenocarcinoma. Mechanistically, miR-483-5p is activated by the WNT/β-catenin signaling pathway and exerts its prometastatic function by directly targeting the Rho GDP dissociation inhibitor alpha (RhoGDI1) and activated leukocyte cell adhesion molecule (ALCAM), two putative metastasis suppressors. Furthermore, we found that downregulation of RhoGDI1 enhances expression of Snail, thereby promoting EMT. Importantly, miR-483-5p levels are positively correlated with β-catenin expression, but are negatively correlated with the levels of RhoGDI1 and ALCAM in human lung adenocarcinoma. Our findings reveal that miR-483-5p is a critical β-catenin–activated prometastatic miRNA and a negative regulator of the metastasis suppressors RhoGDI1 and ALCAM. Cancer Res; 74(11): 1–12. ©2014 AACR.

Introduction

Tumor metastases are responsible for approximately 90% of all cancer-related deaths (1). Metastasis is a complex process by which cancer spreads from the place at which it first arose as a primary tumor to distant locations in the body. Metastasis depends on the cancer cells acquiring two separate abilities—increased motility and invasiveness (1). The epithelial–mesenchymal transition (EMT), a process in which epithelial cells lose their polarity and are converted into a mesenchymal phenotype, is regarded as a critical event during tumor metastasis (2, 3). The identification and characterization of molecules that control EMT, cell motility, and invasiveness are critical to our understanding of cancer dissemination. Critical regulators of the metastatic process include both proteins and microRNAs (miRNA).

WNTs and their downstream effectors regulate various processes that are important for cancer progression (4). Activation of Wnt/β-catenin signaling in cancer often drives a transcriptional program such as transcriptional repressor of E-cadherin, Snail that is reminiscent of an EMT, which can promote cell migration and invasiveness (5). The dysregulation of the Wnt/β-catenin pathway has been observed in various forms of cancer. It has been recently shown that overexpression of WNTs and their downstream effectors are associated with poor prognosis in patients with non–small cell lung carcinoma (NSCLC) and involved in metastasis of lung cancer, the most common cause of cancer-related mortality worldwide (6–9). The mechanisms through which Wnt/β-catenin regulates EMT and tumor metastasis, however, are currently not fully understood.

Another set of molecules that play crucial roles in metastasis are miRNA. miRNAs function as 21 to 24 nucleotide guides that regulate the expression of miRNAs containing complementary sequences. Studies have documented the role of miRNAs in the processes involved in metastasis, including cellular proliferation, migration and invasion, and EMT (10–12). The link between miRNAs and metastasis was first reported when miR-10b was shown to be involved in the promotion of breast cancer metastasis by direct targeting HOXD10 (13). This was followed by the discovery that miRNAs can also have a suppressive effect on metastasis, as increased mir-335 expression inhibited metastatic breast cancer cell invasion (14). More recently, several miRNAs such as miR-200, miR-205, and miR-221/222 have been shown to be involved in EMT (15, 16). Given that many miRNAs are deregulated in cancers but have not yet been further studied, it is expected that more miRNAs will emerge as critical players in the etiology and progression of cancer (17).

Recently, miR-483 has been shown to be dysregulated and be associated with poorer disease-specific survival in some cancers (18–22). But the role of miR-483 in lung cancer metastasis and the molecular mechanisms by which miR-483 regulates lung cancer metastasis are not known. Here, we demonstrate that upregulation of miR-483-5p in human
lung adenocarcinoma is correlated with the progression of the tumor. miR-483-5p is activated by WNT/β-catenin signaling to promote lung adenocarcinoma cell EMT, invasion, and metastasis through direct targeting of the Rho GDP dissociation inhibitor alpha (RhoGDI1) and activated leukocyte cell adhesion molecule (ALCAM) in vitro and in vivo. We have also shown that downregulation of RhoGDI1 enhances expression of Snail, the most important transcriptional repressor of E-cadherin, thereby promoting EMT. Our findings identify miR-483-5p as a β-catenin-activated pro-metastatic miRNA and provide new insights into the molecular functions of miR-483 and RhoGDI1 as well as their regulatory mechanisms in metastasis.

Materials and Methods

Cell culture

Human NSCLC cell lines A549 and PC9 were maintained in Dulbecco’s Modified Eagle Medium and RPMI-1640, respectively, and supplemented with 10% FBS (Invitrogen-GIBCO) and incubated at 37°C in 5% CO2. They had been passed for less than 6 months in culture when the experiments were carried out. Cell lines were characterized using DNA analysis by short tandem repeat fingerprinting.

Animal studies

Five-week-old female BALB/c nude mice were purchased from the Animal Center of Sun Yat-Sen University (Guangzhou, China). To evaluate in vivo tumor growth, 1 × 106 cells, which were suspended in 1:2 Matrigel (BD Biosciences) plus normal growth media, were injected subcutaneously into the flanks of nude mice (n = 5). For experimental metastasis assays, age-matched female nude mice were injected with 5.0 × 105 cells (resuspended in PBS) via the tail vein. The fluorescence emitted by cells was collected and imaged through a whole-body GFP imaging system (Lighttools). Subcutaneous tumor and lung metastases were detected by hematoxylin and eosin (H&E) staining.

Invasion and motility assays

For motility assays, 5.0 × 105 cells were placed in the top chamber of each insert (BD Biosciences) with 8.0-μm pores; for invasion assays, 1.0 × 105 cells were seeded in a Matrigel-coated chamber (BD Biosciences). Cells were seeded in serum-free medium and translocated toward complete growth media. After 24 hours of incubation at 37°C, cells that had migrated or invaded were fixed and stained in dye solution containing 20% methanol violet and 0.1% crystal. The cells that had migrated or invaded were imaged using a BH-2 inverted microscope (Olympus).

ImmunobLOTS

Cells were lysed in 2 × SDS sample buffer on ice and total proteins were further analyzed by SDS–PAGE and transferred to a polyvinylidene difluoride membrane, and probed with antibodies against β-actin (Santa Cruz Biotechnology, Inc.), ALCAM (Sino Biological), RhoGDI1, Fibronectin, Snail (Proteintech), N-cadherin (Epitomies), E-cadherin, and β-catenin (Cell Signaling Technology). After incubation with primary antibodies, the membranes were washed with TBS/0.05% Tween-20 and incubated with horseradish peroxidase–conjugated secondary antibodies at room temperature for 1 hour. Proteins were detected by enhanced chemiluminescence substrates (PerkinElmer).

Rac1/cdc42 activation assay

Cells were harvested in magnesium-containing lysis buffer 3 days after transfection, and the lysates were sonicated for 5 seconds and centrifuged for 30 minutes at 18,000 × g and 4°C following the manufacturer’s specifications for the Rac/Cdc42 Assay Reagent Kit (Upstate Biotechnology, Inc.). A total of 10 μg Rac/Cdc42 assay reagent was added to 600 μL protein lysate and gently rocked at 4°C for 30 minutes. PAK-21-agarose conjugates were collected by centrifugation for 5 seconds at 14,000 × g at room temperature and washed three times with 500 μL magnesium-containing lysis buffer, and bound protein was eluted in 25 μL SDS–PAGE sample buffer. Western blotting of these samples and of 10 μL of the original lysate as a loading control was performed using standard protocols.

Luciferase assays

A total of 5.0 × 104 A549 cells were cotransfected with 50 ng of the indicated pMIR–REPORT luciferase construct and 50 ng of a pMIR–REPORT β-gal normalization control. All cells were also transfected with miR-483-5p mimics or negative control. Lysates were collected 36 hours after transfection, and β-gal and firefly luciferase activities were measured with β-gal and the Luciferase Reporter System (Promega).

miRNA detection

Total RNA, inclusive of the small RNA fraction, was extracted from cultured cells with a Tissue Total RNA Extraction Kit (GenePharma). Reverse transcription reactions were carried out using M-MLV reverse transcriptase (Invitrogen). Real-time PCR was performed on an Applied Biosystem StepOnePlus, using a SYBR Green 1 Real-Time PCR Kit (GenePharma) for miR-483-5p. The relative expression levels of miRNAs in each sample were calculated and quantified using the 2–ΔΔCT method after normalization for expression of the positive control.

In situ hybridization and immunohistochemistry of human TMAs

Lung adenocarcinoma tissue microarrays (HLuc-Ade150CS; Shanghai Outdo Biotech) were constructed with 75 formalin-fixed, paraffin-embedded lung adenocarcinoma tissues and their corresponding adjacent lung tissues. The protocol for detection of miRNAs by in situ hybridization (ISH) has been previously published (23). The sequences of the probes (Exiqon) for hsa-miR-483-5p containing the locked nucleic acid/digoxigenin–modified bases were as follows: CTGCCCTTTC- TTCTCCCGTCTCT. Immunohistochemical staining for proteins was carried out as previously described (24, 25). The intensity of miR-483-5p and proteins staining in epithelial cells of the 75 lung adenocarcinoma samples was scored using a semiquantitative scale as previously described (24, 25). Shortly, immunostaining was defined as “high” if the immunoreactivity was observed in 10% or more of the cells in paraffin sections;
and motility of lung adenocarcinoma cells
miR-483 regulates EMT and enhances the invasiveness between miR-483-5p and lung adenocarcinoma metastasis. The results suggest a strong correlation demonstrated the strongest miR-483-5p expression, with all staining. The tumors from patients with distant metastases showed low miR-483-5p staining, whereas most tumors (54.8%) metastases. Most of the tumors from metastasis-free patients (75.0%) stained. Furthermore, miR-483-5p was signifi- cantly upregulated in malignant as compared with benign tumors. All 75 patients were divided into three groups based on clinicopathologic features associated with lymph node and distant metastases. Most of the tumors from metastasis-free patients (75.0%) showed low miR-483-5p staining, whereas most tumors (54.8%) from patients with metastases demonstrated high miR-483-5p staining. The tumors from patients with distant metastases demonstrated the strongest miR-483-5p expression, with all tumors showing high miR-483-5p staining (Fig. 1A; Supplementary Table S2). The results suggest a strong correlation between miR-483-5p and lung adenocarcinoma metastasis.

miR-483 promotes lung adenocarcinoma metastasis
To identify the role of miR-483 in lung adenocarcinoma metastasis, we transfected lung adenocarcinoma cells A549 or PC9 with pcDNA 3.1 (+)-miR-483 or the control vector. Ninety-six hours after transfection, A549 cells overexpressing miR-483 turned from round into a spindle-like mesenchymal phenotype (Fig. 1B). In addition, we visualized the actin cytoskeleton by phalloidin staining. The result demonstrated that F-actin distribution was rearranged in these cells from a cortical to a stress-fiber pattern, a hallmark of the mesenchymal phenotype (Fig. 1B). Immunofluorescent staining of these cells for N-cadherin–revealed expression was increased, a typical marker of EMT (Fig. 1B). miR-483 also significantly reduced the E-cadherin, but increased the fibronectin levels (Fig. 1C), another hallmark of the mesenchymal phenotype. Although miR-483 can induce EMT, it has no obvious inhibitory effect on the proliferation of lung adenocarcinoma cells (Supplementary Fig. S2A and S2B), suggesting that growth arrest may not be required for miR-483–induced EMT in these cells.

The effect of miR-483 on cell motility and invasion was tested by Transwell assays. The results showed that ectopic miR-483 expression significantly promoted A549 (Fig. 1D) and PC9 (Fig. 1E) cells migration and invasion as measured by crystal violet staining. Taken together, these in vitro results suggest that miR-483 induces EMT and promotes cancer cell migration and invasion.

miR-483-5p, but not miR-483-3p, significantly induces EMT and promotes lung adenocarcinoma cell migration and invasion
The same hairpin RNA structure can generate mature products from each strand, termed 5p and 3p, that have different sequences and, therefore, target different mRNAs with different function (26). To determine which strand of miR-483 is involved in lung adenocarcinoma cells EMT, migration, and invasion, we introduced the synthesized miRNA mimics and inhibitor into lung adenocarcinoma cells. We found that miR-483-5p induced EMT in A549 as shown by the changes in cell morphology and F-actin distribution, whereas miR-483-3p did not (Supplementary Fig. S3). Similar to miR-483, miR-483-5p significantly reduced the E-cadherin, but increased the fibronectin and N-cadherin levels, whereas miR-483-3p did not (Fig. 1F).

We also found that miR-483-5p, but not miR-483-3p, promoted A549 and PC9 cell migration and invasion (Fig. 1G and H). Accordingly, silencing of miR-483-5p by transfection of cells with miR-483-5p inhibitors led to a significant decrease in cell migration and invasion (Fig. 1G and H). Taken together, these in vitro results suggest that miR-483-5p, but not miR-483-3p, induces EMT and promotes cell migration and invasion.

miR-483-5p promotes lung adenocarcinoma metastasis
Given these positive correlations between miR-483-5p levels and metastasis-relevant traits in vitro, we next assessed the potential of prometastatic roles for miR-483-5p in vivo. We engineered lung adenocarcinoma cells to stably overexpress miR-483-5p by lentivirus. As expected, ectopic miR-483-5p did not affect proliferation in vitro (Supplementary Fig. S2C and S2D), but did enhance invasion and motility (Fig. 2A and B). Hence, miR-483-5p enhances in vitro metastatic ability.

Because of its effects on in vitro traits associated with high-grade malignancy, we asked whether ectopic miR-483-5p could promote metastasis in vivo. Thus, the modified lung adenocarcinoma cells with miR-483-5p stable overexpression were injected into the flanks of nude mice. As shown in Fig. 2C, the control cells generally formed oval-shaped intracranial tumors and exhibited sharp edges when expanding as spheroids. In contrast, tumors formed by the miR-483-5p–transduced lung adenocarcinoma cells exhibited highly invasive morphology.

Statistical analysis
Statistical analysis was conducted using the SPSS statistical software program (Version 13.0; SPSS Inc.). The association between miR-483-5p and protein expression was analyzed by the χ² test. Differences between groups were analyzed using the Student t test and one-way ANOVA, or if the data violated a normal distribution, by the nonparametric Mann–Whitney test, and a level of P < 0.05 was considered statistically significant. Data are presented as mean ± SEM unless otherwise indicated. Correlations were performed using Pearson correlation analysis.

Results
Upregulation of miR-483-5p is correlated with the progression of human lung adenocarcinoma
miR-483 has been shown to be dysregulated in some cancers recently. To identify the role of miR-483-5p in lung cancer metastasis, we first analyzed the correlation between miR-483-5p expression and clinicopathologic parameters in patients with lung adenocarcinoma based on the results from tissue microarray analysis (TMA). An ISH TMA was used in this study, which was constructed with 75 formalin-fixed, paraffin-embedded lung adenocarcinoma tissues and their corresponding adjacent lung tissues (Fig. 1A; Supplementary Fig. S1; Supplementary Table S1 and S2). The results indicated that the level of miR-483-5p in lung adenocarcinoma was markedly enhanced as compared with that in adjacent tissues (Fig. 1A; Supplementary Table S2). Most of the adjacent lung tissues (97.3%) showed low and only 2.7% showed high miR-483-5p staining, whereas 37% tumors demonstrated high miR-483-5p staining. Furthermore, miR-483-5p was significantly upregulated in malignant as compared with benign tumors. All 75 patients were divided into three groups based on clinicopathologic features associated with lymph node and distant metastases. Most of the tumors from metastasis-free patients (75.0%) showed low miR-483-5p staining, whereas most tumors (54.8%) from patients with metastases demonstrated high miR-483-5p staining. The tumors from patients with distant metastases demonstrated the strongest miR-483-5p expression, with all tumors showing high miR-483-5p staining (Fig. 1A; Supplementary Table S2). The results suggest a strong correlation between miR-483-5p and lung adenocarcinoma metastasis.

miR-483 regulates EMT and enhances the invasiveness and motility of lung adenocarcinoma cells in vitro
To identify the role of miR-483 in lung adenocarcinoma metastasis, we transfected lung adenocarcinoma cells A549 or PC9 with pcDNA 3.1 (+)-miR-483 or the control vector. Ninety-six hours after transfection, A549 cells overexpressing miR-483 turned from round into a spindle-like mesenchymal phenotype (Fig. 1B). In addition, we visualized the actin cytoskeleton by phalloidin staining. The result demonstrated that F-actin distribution was rearranged in these cells from a cortical to a stress-fiber pattern, a hallmark of the mesenchymal phenotype (Fig. 1B). Immunofluorescent staining of these cells.
with the borders displaying a palisading pattern of tumor cell distribution and forming spike-like structures invading into the surrounding regions. Thus, miR-483-5p enhances local invasion. Importantly, GFP expression was maintained in the tumor cells and miR-483-5p overexpression had no obvious effect on the proliferation (Supplementary Fig. S2E).

We further determined whether the impact of miR-483-5p on metastasis was also attributable to effects on later steps of the invasion–metastasis cascade, independent of its influence on local invasion. Thus, we injected miR-483-5p–expressing A549 cells directly into the circulation of mice, thereby circumventing the initial steps of local invasion and intravasation. Fifty-five days after tail vein injection, miR-483-5p–expressing A549 cells generated much more lung metastases than controls (Fig. 2D and E). These observations indicated that the ability of miR-483-5p–expressing cells to result in more invasive primary tumors, and to seed more metastases, is a specific consequence of the biologic activities of miR-483-5p.
Silencing of miR-483-5p inhibits lung adenocarcinoma metastasis

We next asked whether inhibition of miR-483-5p prevents the acquisition of aggressive traits. To do so, we engineered lung adenocarcinoma cells to stably inhibit miR-483-5p with a lentivirus-mediated antagomir. The results showed that suppression of miR-483-5p decreased motility and invasion (Fig. 3A and B); however, cell proliferation was unaffected in vitro (Supplementary Fig. S2C and S2D). Thus, miR-483-5p antagomir had the opposite effect with miR-483-5p.

We asked whether inhibition of miR-483-5p could decrease local invasion. Thus, A549 and PC9 cells with miR-483-5p inhibited were injected into the orthotopic site of nude mice. As expected, primary tumors derived from miR-483-5p antagomir-expressing cells were well encapsulated and less invasive (Fig. 3C). Furthermore, inhibition of miR-483-5p failed to alter in vivo proliferation and primary tumor growth (Supplementary Fig. S2F).

Then, we asked whether loss of miR-483-5p activity also inhibits metastasis by intervening at steps of the invasion–metastasis cascade subsequent to local invasion. Thus, we intravenously injected mice with miR-483-5p antagomir-expressing A549 cells. Strikingly, miR-483-5p antagomir-expressing A549 cells metastasized to the lungs were largely devoid; cells with impaired miR-483-5p activity formed fewer lesions than controls (Fig. 5D and E).

Together, these data extended and reinforced our ectopic expression studies by demonstrating that miR-483-5p affects local invasion, early post-intravasation events, and metastatic colonization.

miR-483-5p directly targets the RhoGDI1 and ALCAM 3′ UTR

The ability of miR-483-5p to promote multiple steps of the invasion–metastasis cascade might derive from its ability to regulate genes involved in diverse aspects of metastatic dissemination. We used two strategies to identify the effectors of miR-483-5p. On the one hand, we applied two algorithms that predict the mRNA targets of a miRNA–PicTar (27) and TargetScan (28). On the basis of the representation of miR-483-5p sites in their 3′ untranslated regions (UTR), >100 mRNAs were predicted to be regulated by miR-483-5p. Among these candidates, seven genes (ALCAM, FOXJ2, FOXO3, RhoGDI1, NDRG2, SOX11, and TFAP2B) were
involved in the suppression of cancer metastasis. On the other hand, we applied a proteomic approach using two-dimensional gel electrophoresis to identify proteins suppressed upon enhanced miR-483-5p expression in A549 cells (Fig. 4B and Supplementary Fig. S4). The putative tumor suppressors RhoGDI1 and ALCAM emerged as the most strongly downregulated proteins (Fig. 4B).

To determine whether miR-483-5p targets these genes directly, we cloned the 3′UTRs of seven putative miR-483-5p targets into a luciferase construct. Reporter assays using miR-483-5p–expressing A549 cells revealed that miR-483-5p repressed two of the UTRs: ALCAM, RhoGDI1 (Fig. 4A). Mutations of the putative miR-483-5p site(s) in these two 3′UTRs abrogated responsiveness to miR-483-5p (Fig. 4C–E). In the case of RhoGDI1, in which 3′UTR contains two putative miR-483-5p sites, mutation of either motif can not fully abolished miR-483-5p responsiveness. Mutation of the two sites completely abolished the ability of miR-483-5p to inhibit luciferase activity. These results suggest that both of these predicted sites contribute equally to miR-483-5p–mediated RhoGDI1 reduction.

In accordance with these results, we observed a clear decrease in endogenous RhoGDI1 and ALCAM protein in lung adenocarcinoma cells with miR-483 overexpression (Fig. 4F). Furthermore, overexpression of miR-483-5p, but not miR-483-3p, significantly decreased the expression levels of RhoGDI1 and ALCAM protein (Fig. 4F). Inhibition of miR-483-5p significantly increased the expression levels of RhoGDI1 and ALCAM protein in A549 cells. Taken together, these results suggest that miR-483 can downregulate RhoGDI1 and ALCAM expression by directly targeting their 3′UTR.

Exogenous expression of miR-483-5p enhances the activation of Rac and Cdc42

Given that RhoGDI1 is the negative regulator of Rho GTPases such as Rac1 and Cdc42, we next determined whether miR-483-5p expression changes the activities of Rac and Cdc42 GTPases. As the PAK-21 protein binds to only activated (GTP-bound) forms of active GTPases, we used a PAK-21 pulldown approach to assay GTPase activity upon transfection of miR-483-5p mimics. Amounts of GTP-bound Rac1 and Cdc42 were determined by SDS–PAGE followed by immunoblotting by using published methodologies (29). As seen in Fig. 4G, transfection of miR-483-5p mimics markedly increased the amount of active Rac1 and Cdc42, whereas the protein levels of these Rho GTPases were not altered.
miR-483-5p overexpression and RhoGDI1 inhibition produce similar changes, which are rescued by RhoGDI1 ectopic expression in vitro

We further found that knockdown of RhoGDI1 produced similar changes in invasion and motility assay to that of miR-483-5p overexpression, whereas knockdown of ALCAM promoted invasion less effectively (Fig. 5A–D). To determine whether these effects depend specifically on RhoGDI1 or ALCAM suppression, we used an expression construct that encodes the entire RhoGDI1 or ALCAM coding sequence but lacks the 3'UTR. Ectopic expression of ALCAM with this construct partially rescued miR-483-5p–mediated invasion in miR-483-5p–overexpressing cells (Fig. 5B and D). Surprisingly, reexpression of RhoGDI1 completely inhibited miR-483-5p–mediated invasion (Fig. 5A and C). This suggests that, after miR-483-5p overexpression, a decrease in RhoGDI1 is required for cells to show increased invasiveness.

Then we ask whether RhoGDI1 or ALCAM connects miR-483-5p and EMT. Interestingly, A549 cells changed from round to a spindle-like mesenchymal phenotype after knockdown of RhoGDI1 (Fig. 5E), which mimic the effect of miR-483-5p on EMT, whereas ALCAM did not (Supplementary Fig. S5).
Furthermore, knockdown of RhoGDI1 also significantly reduced the E-cadherin, but increased the N-cadherin levels (Fig. 5F). The loss of E-cadherin is the hallmark of EMT. Several transcription factors have been implicated in the transcriptional repression of E-cadherin. Snail is the first discovered and most important transcriptional repressor of E-cadherin (30). Furthermore, snail was found to promote tumor progression in NSCLC (31). Surprisingly, we found that Snail was upregulated by miR-483-5p and downregulated by anti–miR-483-5p (Fig. 5G). Given that RhoGDI1 may connect miR-483-5p and EMT, we ask whether RhoGDI1 connects miR-483-5p and Snail. Interestingly, knockdown of RhoGDI1 produced a similar change in Snail expression to that of miR–483-5p (Fig. 5F). Taken together, these data indicated that the ability of miR-483-5p to promote metastasis is attributable, in significant part, to its capacity to inhibit RhoGDI1.

miR-483-5p is regulated by WNT/β-catenin signaling in lung adenocarcinoma cells

It has been reported that miR-483 expression in colon cancer cells can be driven by β-catenin (32). To further confirm these results in lung adenocarcinoma cell, we stabilized β-catenin protein by treating A549 cells with lithium chloride (LiCl), an inhibitor of GSK3β, which is responsible for β-catenin degradation. It was found that the expression of the miR-483-5p was significantly activated by LiCl treatment (Fig. 6A). Furthermore, we transiently knocked down β-catenin in A549 cells. Quantitative real-time PCR (qRT-PCR) verified a significant increase in miR-483-5p expression.
reduction of miR-483-5p expression in cells transfected with β-catenin siRNA (Fig. 6B and C).

It is reported that knockdown of β-catenin decreases the invasiveness of cancer cell (33). The invasion assay results showed that knockdown of β-catenin decreased the invasiveness of A549 cells (Fig. 6D and E). Furthermore, reexpression of miR-483-5p restored the decreased invasiveness of A549 cells. Taken together, these results suggest that miR-483-5p expression can be driven by WNT/β-catenin signaling, and may play a role in WNT/β-catenin–mediated metastasis.

Clinical associations of miR-483-5p with RhoGDI1, ALCAM, and β-catenin expression

We next determined whether there was an association between the expression levels of miR-483-5p and its targets in human lung adenocarcinoma tissues. It was found that miR-483-5p levels were negatively correlated with the levels of RhoGDI1 and ALCAM (Fig. 7A and B). Furthermore, we analyzed the association between RhoGDI1/ALCAM expression and tumor grades and metastasis, and the results revealed a negative correlation between RhoGDI1/ALCAM and tumor grades (Supplementary Table S3). These results further implicate that miR–483-5p plays an important role in lung adenocarcinoma metastasis by targeting RhoGDI1 and ALCAM.

To demonstrate the relationship between WNT/β-catenin signaling and miR–483-5p in clinical samples, we further examined the β-catenin expression in lung cancer by performing immunohistochemical staining in these clinical samples (Fig. 7; Supplementary Table S2). Interestingly, our results showed a positive correlation between miR–483-5p and β-catenin.

Collectively, our findings indicate that WNT/β-catenin signaling–regulated miR–483-5p and its targets play a part in primary tumor formation and the metastatic process.

Discussion

On the basis of our results, we propose that miR–483-5p, which is upregulated by WNT/β-catenin signaling, promotes EMT and lung adenocarcinoma metastasis through direct
targeting of RhoGDI1 and ALCAM in vitro and in vivo. Moreover, we found that downregulation of RhoGDI1, a direct and functional target of miR-483-5p, can markedly increase Snail expression, thereby promoting EMT. These findings provide new insights into the molecular functions of miR-483 as well as the role of RhoGDI1 in metastasis.

Lung cancer is the most common cause of cancer-related mortality in men and women worldwide. NSCLC accounts for 70% to 80% of lung cancer diagnoses and the disease is generally diagnosed at an advanced stage. Distant metastases, rather than the primary tumors from which these lesions arise, are responsible for >90% of carcinoma-associated mortality (1). Up to date, the molecular mechanisms underlying the development of lung cancers are still poorly understood. Therefore, a better understanding of the molecular mechanisms involved in tumor formation and development will be helpful to develop novel therapeutic targets and strategies for the treatment of human lung cancers.

miR-483 was first identified in human fetal liver (34). Recently, miR-483 has been shown to be dysregulated and associated with poorer disease-specific survival in some cancers (18–22). Despite the oncogenic role of miR-483 has been implicated by previous studies, the role of miR-483 in tumor metastasis and molecular mechanisms through which miR-483 regulates metastasis are not known. Here, we show that miR-483-5p was upregulated in lung adenocarcinoma, and, moreover, its expression levels were higher in malignant than benign tumors. And we identified miR-483 as a prometastatic miRNA and a negative regulator of the key metastasis suppressors RhoGDI1 and ALCAM.

The dysregulation of the Wnt/β-catenin pathway has been observed in various forms of cancers. It has been recently shown that altered β-catenin expression, or WNT1, WNT3A, and WNT5A overexpression, are associated with poor prognosis in patients with NSCLC (6–9). hsa-mir-483 is located within intron 2 of the IGF2 gene. In colon cancer cells, miR-483 locus expression can be driven by β-catenin independently from IGF2 (32). Here, we demonstrate that Wnt/β-catenin signaling activates miR-483-5p to promote EMT and enhance the invasiveness and motility of lung adenocarcinoma cells. Specifically, it is miR-483-5p, but not miR-483-3p, that significantly induces EMT and promotes lung adenocarcinoma cell migration and invasion. Therefore, this study revealed a novel mechanism by which Wnt/β-catenin signaling contributes to cancer metastasis.

Rho GTPases contribute to multiple cellular processes that could affect cancer progression, including cytoskeletal dynamics, cell adhesion, and migration (35). Rho GTPases are...
activated by the exchange of bound GDP for ambient GTP, which is stimulated by guanine nucleotide exchange factors (GEF) and are inactivated by hydrolysis of bound GTP to GDP catalyzed by GTPase-activating proteins (GAP). This activity cycle is regulated by GDIs, which act to sterically shield the Rho GTPases from the action of GEFs and GAPs (37, 38). Recent studies indicate that RhoGDI1 functions as a candidate metastasis suppressor, which is frequently downregulated in hepatocellular carcinoma and breast cancer (37, 38). Our findings showed that RhoGDI1 is a direct and functional target for miR-483-5p, which can directly suppress RhoGDI1 expression and, thus, in turn activate Rac1 and Cdc42. Downregulation of RhoGDI1 by miR-483-5p increases cell motility and invasiveness and contributes to metastases formation. Furthermore, we found that downregulation of RhoGDI1 induced the expression of Snail, and thereby promoted EMT. The regulation of EMT by RhoGDI1 has not been reported in previous studies. These findings further establish RhoGDI1 as a critical metastasis suppressor.

ALCAM is involved in both homotypic and heterotypic (to lymphocyte cell surface receptor CD6) adhesion (39). It has been implicated in pathologic states, such as cancer metastasis, but its role remains inconsistent. ALCAM was found to be upregulated in melanoma, colon cancer, esophageal squamous cell carcinoma, and gastric cancer and plays a role in promoting motility and migration (40–43). In prostate carcinoma, ALCAM was upregulated in low-grade tumors, but downregulated in high-grade tumors (44). In this study, we discovered that ALCAM was downregulated and targeted by miR-483-5p in human lung adenocarcinoma. Furthermore, transfection of mimics of miR-483-5p and knockdown of ALCAM significantly increased the migration of lung adenocarcinoma cells. Interestingly, we found a negative correlation between ALCAM and RhoGDI1 expression levels. Considering our own and these previous published findings, we postulate that miR-483-5p–dependent changes in ALCAM could contribute to the invasion and metastasis of cancer cells.

In the present study, we demonstrated the roles and mechanism of miR-483 in lung adenocarcinoma metastasis. Our findings identify a mechanism for downregulating RhoGDI1 and ALCAM, and indicate that elevated expression of miR-483, which is upregulated by WNT/β-catenin signaling, contributes to EMT and metastasis. As shown by other researchers, downregulation of ALCAM and RhoGDI1 increases cancer cells motility and invasiveness. In addition, we found that downregulation of RhoGDI1 enhances the induction of Snail and promotes EMT. Thus, we reason that the role of RhoGDI1 in metastasis may be more profound than previously thought. This study also revealed a novel mechanism by which Wnt/β-catenin signaling contributes to cancer metastasis. Because distant metastases are responsible for patient mortality in the vast majority of human carcinomas, the ability of miR-483 to impede metastasis may prove clinically useful.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: Q. Song, Z. Chen, X. Bai
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Q. Song, Y. Xu, X. Fan
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Q. Song, Y. Xu
Writing, review, and/or revision of the manuscript (e.g., statistical analysis, biostatistics, computational analysis): Q. Song, X. Bai
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Q. Song, C. Yang, J. Chen, Y. Zhang, P. Lai, J. Lin, M. Li
Study supervision: W. Ma, S. Luo, X. Bai

Acknowledgments
The authors thank Prof. Xiqun Han from the Department of Pathology for contributive suggestions.

Grant support
This work was supported by the State Key Development Program for Basic Research of China (2013CB945203), National Natural Sciences Foundation of China (61270088, 31271271), the Program for Changjiang Scholars and Innovative Research Team in University (IRT1142), and “Outstanding Leadership Grant” from Guangdong Province (C1000925).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 5, 2013; revised March 4, 2014; accepted March 20, 2014; published OnlineFirst April 7, 2014.


Song et al.


miR-483-5p Promotes Invasion and Metastasis of Lung Adenocarcinoma by Targeting RhoGDI1 and ALCAM

Qiancheng Song, Yuanfei Xu, Cuilan Yang, et al.

Cancer Res Published OnlineFirst April 7, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-2193

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/04/14/0008-5472.CAN-13-2193.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2014/05/14/0008-5472.CAN-13-2193. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.